KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
A phase 3 trial testing KL-A167 in nasopharyngeal carcinoma, active and no longer recruiting.
Overview
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT05294172, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting when checked on 2026-09-11. Official title: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomised, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. Planned enrolment is 295 participants (actual). The study started in 2022-06-07 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Shares Sichuan Kelun-Biotech and the tag ctgov-ingest.
- TrialA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.
- TreatmentA166
Shares Sichuan Kelun-Biotech and the tag ctgov-ingest.
- TreatmentMRG003
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.
- TreatmentHMBD-001
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.
- TreatmentYL201
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.